Interstitial Lung Disease Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies

 Breaking News
  • No posts were found

Interstitial Lung Disease Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies

May 11
19:37 2023
Interstitial Lung Disease Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 120+ key pharma and biotech companies are working on 120+ pipeline drugs in the Interstitial Lung Disease therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Interstitial Lung Disease Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Interstitial Lung Disease Market. 

The Interstitial Lung Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Interstitial Lung Disease Pipeline Analysis

Interstitial Lung Disease Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Interstitial Lung Disease and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Interstitial Lung Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Intravenous

  • Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

  • Small molecule

  • Cell Therapy

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Ongoing Clinical & Commercial Activities will Affect the Interstitial Lung Disease Therapeutic Segment @

Interstitial Lung Disease Therapeutics Landscape

There are approx. 120+ key companies developing therapies for Interstitial Lung Disease. Currently, Pfizer is leading the therapeutics market with its Interstitial Lung Disease drug candidates in the most advanced stage of clinical development.

The Leading Players in the Interstitial Lung Disease Therapeutics Market Include:

  • Roche

  • aTyr Pharma

  • Boehringer Ingelheim

  • FibroGen

  • LTT Bio-Pharma

  • Bristol-Myers Squibb

  • Prometheus Biosciences

  • HEC Pharm

  • Bayer

  • Insmed

  • Avalyn Pharma

  • PureTech Health

  • Novartis

  • Horizon

  • MediciNova

  • Endeavor BioMedicines

  • Pliant Therapeutics

  • Kadmon Pharmaceuticals

  • GenKyoTex

  • Lung Therapeutics

  • AdAlta

  • Ark Biosciences

And Many Others

Interstitial Lung Disease Emerging and Marketed Drugs Covered in the Report Include:

  • DWN12088: Daewoong Pharmaceutical

  • LYT-100: PureTech

  • BMS-986278: Bristol-Myers Squibb

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Interstitial Lung Disease Current Treatment Patterns

4. Interstitial Lung Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Interstitial Lung Disease Late Stage Products (Phase-III)

7. Interstitial Lung Disease Mid-Stage Products (Phase-II)

8. Interstitial Lung Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Interstitial Lung Disease Discontinued Products

13. Interstitial Lung Disease Product Profiles

14. Key Companies in the Interstitial Lung Disease Market

15. Key Products in the Interstitial Lung Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Interstitial Lung Disease Unmet Needs

18. Interstitial Lung Disease Future Perspectives

19. Interstitial Lung Disease Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic healthcare market today @ Healthcare Partner Identification Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States